These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15340001)

  • 1. Statin induced proteinuria: renal injury or renoprotection?
    Agarwal R
    J Am Soc Nephrol; 2004 Sep; 15(9):2502-3. PubMed ID: 15340001
    [No Abstract]   [Full Text] [Related]  

  • 2. An assessment of statin safety by nephrologists.
    Kasiske BL; Wanner C; O'Neill WC;
    Am J Cardiol; 2006 Apr; 97(8A):82C-85C. PubMed ID: 16581334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of statin-associated proteinuria.
    Tiwari A
    Drug Discov Today; 2006 May; 11(9-10):458-64. PubMed ID: 16635810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of statins on renal function.
    Agarwal R
    Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin safety: lessons from new drug applications for marketed statins.
    Jacobson TA
    Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin therapy in patients with chronic kidney disease: to use or not to use.
    Steinmetz OM; Panzer U; Stahl RA; Wenzel UO
    Eur J Clin Invest; 2006 Aug; 36(8):519-27. PubMed ID: 16893373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propensity scores and observational research.
    O'Connor AS; Love TE
    Am J Med; 2006 Mar; 119(3):e15-6; author reply e17-8. PubMed ID: 16490455
    [No Abstract]   [Full Text] [Related]  

  • 8. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of statins on the progression of atherosclerotic renovascular disease.
    Cheung CM; Patel A; Shaheen N; Cain S; Eddington H; Hegarty J; Middleton RJ; Cowie A; Mamtora H; Kalra PA
    Nephron Clin Pract; 2007; 107(2):c35-42. PubMed ID: 17713349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with proteinuria in renal transplant recipients treated with sirolimus.
    Liew A; Chiang GS; Vathsala A
    Transpl Int; 2009 Mar; 22(3):313-22. PubMed ID: 19054382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gitelman's syndrome presenting as intolerance to statin therapy.
    Freedman DB; Housley D
    Ann Clin Biochem; 2005 May; 42(Pt 3):232-3. PubMed ID: 15949161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin: renal disorders and rhabdomyolysis.
    Prescrire Int; 2007 Apr; 16(88):68-9. PubMed ID: 17458050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
    Navarro-Muñoz M; Bonet J; Bayés B; Lauzurica R; Blanco S; Romero R
    Transplant Proc; 2007 Sep; 39(7):2259-63. PubMed ID: 17889157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and renal diseases: from primary prevention to renal replacement therapy.
    D'Amico G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S148-52. PubMed ID: 16565241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin pleiotropy against renal injury.
    Kostapanos MS; Liberopoulos EN; Elisaf MS
    J Cardiometab Syndr; 2009; 4(1):E4-9. PubMed ID: 19245508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of rosuvastatin.
    Shepherd J; Hunninghake DB; Stein EA; Kastelein JJ; Harris S; Pears J; Hutchinson HG
    Am J Cardiol; 2004 Oct; 94(7):882-8. PubMed ID: 15464670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the mechanisms of statin-induced myopathy.
    Laaksonen R
    Clin Pharmacol Ther; 2006 Jun; 79(6):529-31. PubMed ID: 16765140
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk factors for statin-associated rhabdomyolysis.
    Schech S; Graham D; Staffa J; Andrade SE; La Grenade L; Burgess M; Blough D; Stergachis A; Chan KA; Platt R; Shatin D
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):352-8. PubMed ID: 16892458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
    McKenney JM; Davidson MH; Jacobson TA; Guyton JR;
    Am J Cardiol; 2006 Apr; 97(8A):89C-94C. PubMed ID: 16581336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing statin myopathy.
    Venero CV; Thompson PD
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):121-36. PubMed ID: 19217515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.